| Literature DB >> 36077633 |
Min Suk Chae1, Youngkyung Park1, Jung-Woo Shim1, Sang Hyun Hong1, Joonseon Park2, Il Ku Kang2, Ja Seong Bae2, Jeong Soo Kim2, Kwangsoon Kim2.
Abstract
Few studies have examined the clinical utility of ultrasonography-guided pectoralis nerve block II (PECS II) during wide flap dissection of a robot-assisted transaxillary thyroidectomy (RATT). We assessed the ability of PECS II to reduce postoperative pain. We retrospectively reviewed 62 patients who underwent elective RATT from December 2021 to April 2022 at Seoul St. Mary's Hospital (Seoul, Korea). The patients were divided into a block group (n = 28, 50.9%) and no-block group (n = 27, 49.1%). Pain was measured using a visual analog scale (VAS) at 4, 10, 20, 25, 35, and 45 h after surgery, and the requirements for rescue painkillers in the post-anesthesia care unit and ward were recorded. The VAS scores did not differ significantly between the two groups at 4 h postoperatively. The block group had significantly lower VAS scores at 10 and 25 h (p = 0.017 and p = 0.034, respectively). The block group required fewer painkillers in the post-anesthesia care unit than the no-block group, although the difference was not statistically significant in the ward. PECS II may serve as a new pain relief modality and valuable addition to the current multimodal analgesic strategy for patients undergoing RATT.Entities:
Keywords: PECS II block; robotic surgery; thyroidectomy; transaxillary; visual analogue scale
Year: 2022 PMID: 36077633 PMCID: PMC9454532 DOI: 10.3390/cancers14174097
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Study flow diagram.
Figure 2Extent of flap dissection (blue lines).
Figure 3Advancement of the needle along the anterior axillary line.
Figure 4PECS II (A) between the pectoralis minor and serratus anterior muscles, and (B) between the pectoralis major and minor muscles.
Baseline clinicopathological characteristics.
| Total 55 Patients | |
|---|---|
| Age (years) | 41.5 ± 12.4 |
| Gender | |
| Male | 3 (5.5%) |
| Female | 52 (95.5%) |
| Extent of operation | |
| Lobectomy | 48 (87.3%) |
| Total thyroidectomy | 7 (12.7%) |
| Pathology | |
| PTC | 45 (81.8%) |
| HCC | 1 (1.8%) |
| NIFTP | 3 (5.5%) |
| Follicular adenoma | 4 (7.3%) |
| Graves’ disease | 1 (1.8%) |
| Parathyroid adenoma | 1 (1.8%) |
| Tumor size (cm) | 1.1 ± 1.0 |
| Multifocality | 19/49 (38.8%) |
| ETE | |
| No | 19/49 (38.8%) |
| Minimal | 30/49 (61.2%) |
| Thyroiditis | 25 (45.5%) |
| Harvested LNs | 6.2 ± 3.5 |
| Positive LNs | 1.0 ± 1.6 |
| T stage | |
| T1/T2/T3a | 44 (95.7%)/1 (2.2%)/1 (2.2%) |
| N stage | |
| N0/N1a | 28 (60.9%)/18 (39.1%) |
| TNM stage | |
| Stage I/II | 44 (95.7%)/2 (4.3%) |
Data are expressed as the patient number (%) or mean ± standard deviation. Abbreviations: PTC, papillary thyroid carcinoma; HCC, Hurthle cell carcinoma; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; ETE, extrathyroidal extension; LN, lymph node; T, tumor; N, node; M, metastasis.
Baseline clinicopathological characteristics of the PECS II block and no-block groups.
| Block (n = 28) | No Block (n = 27) | ||
|---|---|---|---|
| Age (years) | 43.8 ± 11.7 | 39.0 ± 12.8 | 0.157 |
| Female | 28 (100%) | 24 (88.9%) | 0.111 |
| Extent of operation | 0.206 | ||
| Lobectomy | 26 (92.9%) | 22 (81.5%) | |
| Total thyroidectomy | 2 (7.1%) | 22 (18.5%) | |
| Pathology | 0.648 | ||
| PTC | 23 (82.1%) | 22 (81.5%) | |
| HCC | 0 | 1 (3.7%) | |
| NIFTP | 2 (7.1%) | 1 (3.7%) | |
| Follicular adenoma | 2 (7.1%) | 2 (7.4%) | |
| Graves’ disease | 1 (3.6%) | 0 | |
| Parathyroid adenoma | 0 | 1 (3.7%) | |
| Tumor size (cm) | 0.9 ± 0.6 | 1.3 ± 1.2 | 0.160 |
| Multiplicity | 11/25 (44.0%) | 8/24 (33.3%) | 0.444 |
| Minimal ETE | 16/25 (64.0%) | 14/24 (58.3%) | 0.684 |
| Thyroiditis | 14 (50.0%) | 11 (40.7%) | 0.491 |
| Harvested LNs | 6.4 ± 3.1 | 5.9 ± 4.0 | 0.651 |
| Positive LNs | 1.0 ± 1.8 | 1.0 ± 1.6 | 1.000 |
| T stage | 0.352 | ||
| T1 | 23 (100%) | 21 (91.3%) | |
| T2 | 0 | 1 (3.7%) | |
| T3a | 0 | 1 (3.7%) | |
| N stage | 0.546 | ||
| N0 | 15 (65.2%) | 13 (56.5%) | |
| N1a | 8 (34.80%) | 10 (43.5%) | |
| TNM stage | 1.000 | ||
| Stage I | 22 (95.7%) | 22 (95.7%) | |
| Stage II | 1 (4.3%) | 1 (4.3%) |
Data are expressed as the patient number (%) or mean ± standard deviation. A statistically significant difference was defined as p < 0.05. Abbreviations: PTC, papillary thyroid carcinoma; HCC, Hurthle cell carcinoma; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; ETE, extrathyroidal extension; LN, lymph node; T, tumor; N, node; M, metastasis.
Postoperative VAS pain scores of the pectoral PECS II and no-block groups.
| Block (n = 28) | No Block (n = 27) | ||
|---|---|---|---|
| VAS + 4 h | 4.2 ± 2.0 | 4.4 ± 2.1 | 0.628 |
| VAS + 10 h | 3.3 ± 1.7 †† | 4.3 ± 1.5 | 0.017 |
| VAS + 20 h | 3.4 ± 1.2 | 4.1 ± 1.4 | 0.053 |
| VAS + 25 h | 2.6 ± 1.3 †† | 3.5 ± 1.7 †† | 0.034 |
| VAS + 35 h | 2.4 ± 1.4 ††† | 2.7 ± 1.2 ††† | 0.350 |
| VAS + 45 h | 2.2 ± 1.5 †† | 2.5 ± 1.0 ††† | 0.511 |
| No. of painkiller used | |||
| In the PACU | 0.7 ± 0.6 | 1.7 ± 0.5 | <0.001 |
| In the ward | 1.0 ± 0.9 | 1.6 ± 1.6 | 0.062 |
Data are expressed as the mean ± standard deviation. A statistically significant difference was defined as p < 0.05. † p < 0.05, †† p ≤ 0.01, ††† p ≤ 0.001 compared to the VAS + 4 h in each group. Abbreviations: VAS, visual analog scale; PACU, post-anesthesia care unit. All patients used (1) Fentanyl as the first pain-killer in PACU, and (2) NSAIDs as the first pain-killer, and only three patients in the ward used Pethidine, an opioid analgesic.
Figure 5VAS scores of the two groups.